期刊文献+

40例使用替加环素的临床用药分析 被引量:10

Analysis of Clinical Use of Tigecycline in 40 Cases
下载PDF
导出
摘要 目的评价使用替加环素的住院患者临床用药情况。方法采用回顾性研究方法,收集浙江省丽水市中心医院2012年1月-2014年12月使用替加环素住院患者的临床资料(基础疾病、细菌学培养结果、联合用药、疗效、不良反应发生情况等),共40例,并对其应用进行合理性评价。结果该院近3年使用替加环素患者的抗感染治疗有效率为42.5%,合理使用率17.5%,基本合理使用率77.5%,不合理使用率5.0%,出现不良反应6例(15.0%)。结论该院住院患者替加环素的使用基本合理;替加环素对各类敏感菌引起的感染临床疗效较好,但不良反应发生率较高,临床应用过程中应引起关注。 Objective To evaluate clinical use of tigecycline in hospital patients. Methods Basic diseases,pathologic examinations,concurrent medication,therapeutic efficacy and side effects of 40 patients in Lishui Central Hospital of Zhejiang Province from January 2012 to December 2014 were analyzed retrospectively. Results The effective rate of patients using tigecycline for anti-infection treatment in hospital was 42. 5%. The rates of rational use,basically rational use and irrational use were 17. 5%,77. 5% and 5. 0%,respectively. Adverse drug reactions occurred in 6 cases of tigecycline use( 15. 0%). Conclusion Clinical use of tigecycline in inpatients was basically reasonable in this hospital. The clinical curative effect of tigecycline was good in a variety of infections caused by sensitive bacteria. However,the incidence of adverse drug reactions was high. Attentions should be paid in clinical application.
出处 《医药导报》 CAS 2017年第1期80-83,共4页 Herald of Medicine
基金 丽水市级公益性技术应用项目(2013JYZB27)
关键词 替加环素 药物不良反应 用药分析 Tigecycline Adverse drug reactions Drug analysis
  • 相关文献

参考文献8

二级参考文献73

  • 1Reinert RR,Low DE,Rossi Flavia,et al.Antimicrobial susceptibility among organisms from the Asia/ Pacific Rim,Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline[J].J Antimicrob Chemother,2007 ;60:1018-1029.
  • 2uzin A,Keeney D,Bradford PA.AdeABC muhidrug efflux pump is associated with decreased susceptibility to tigeeycline in Acinetobact IV calcoaceticus-Acinetobacter baumannii complex[J].J Antimierob Chemother,2007 ;59:1001-1004.
  • 3Joseph J J,Sum P E,Gluzman Y,et al.7-substituted-9substituted amino-6-demethyl-6-deoxytetracyclines[P].Us:5494903a,1996-02-17.
  • 4Fawzi Mahdi B,Zhu T M,Shah Syed M,et al.Tigecyclinecompositions and methods of preparation[P].Wo:2006/099258 A1,2006-09-21.
  • 5Lalitha K,Anthony H,Huang J W,et al.Crystalline solid forms of tigecycline and methods of preeparing same[P].Wo:2006/128150A2,2006-11-30.
  • 6Lalitha K,Phaik-Eng S.Methods Of Purifying Tigecycline[P].WO:2006130431 Al.2006-12-07.
  • 7Sergei F,Slavik Y,Sofia G R.Processes for purifica-tion of tigecucline[P] :WO2008/106234 Al.2008-09-04.
  • 8J·J·赫拉夫卡,Y·格鲁滋曼,V·J·李,等.新颖的7-取代-9-取代氨基-6-去甲基-6-去氧四环素[P] :CN1072172.199305-19.
  • 9Petersen PJ,Brad ford PA, Weiss WJ,et al. In vitro and in vfi)o activ- ities of tigecycline ( GAR-936 ), daptomycin, and comparative antimi- crobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant grampositive pathogens [ J ]. Antimicrob Agents Chemother ,2002,46 ( 8 ) : 2595-2601.
  • 10Zhanel GG, Karlowsky JA, Rubinstein E, et al. Tigecycline : a novel glycylcycline antibiotic[ J]. Expert Rev Anti Infect Ther,2006, 4( 1 ) : 9-25.

共引文献149

同被引文献76

引证文献10

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部